Home / Market News / $ACAD
benzinga Corporate Catalyst Impact 75/100 ● neutral

Acadia Pharmaceuticals Announces USPTO Issued Notice Of Allowance For U.S. Patent Application No. 17/590,496, Titled “Methods and Compositions for Treatment of Rett Syndrome.”

Sep 28, 2026, 8:15 PM UTC · Primary ticker $ACAD

Acadia Pharmaceuticals announced the USPTO issued a Notice of Allowance for a patent covering weight-banded dosing of trofinetide, extending patent protection to March 2041. This significantly strengthens the intellectual property for their Rett Syndrome treatment, NUPLAZID, providing a longer period of market exclusivity and reducing competitive threats.

Acadia Pharmaceuticals received a Notice of Allowance from the USPTO for a patent related to the weight-banded dosing of trofinetide, their drug for Rett Syndrome. This is a significant positive development as it extends the patent protection for this key treatment to March 2041, providing a much longer period of market exclusivity. This reduces the risk of generic competition for a crucial revenue-generating product, offering long-term stability and predictability for Acadia's future earnings. For traders, this implies a strengthened competitive moat and potentially higher valuation for ACAD in the long run, while reducing short-term downside risk from patent challenges.

$ACAD positive Extended patent protection for key drug
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.